Mary de Groot

Permanent URI for this collection

https://hdl.handle.net/1805/11673

One in four patients with diabetes will experience depression in their lifetime which is associated with poorer outcomes, greater functional disability, and early mortality. Dr. Mary de Groot is a clinical psychologist whose research is focused on examining the mechanisms that link diabetes and depression as well as the development of accessible interventions to treat depression among adults and socio-economically and culturally diverse populations with diabetes.

Dr. de Groot’s Program ACTIVE (Adults Coming Together to Increase Vital Exercise) is a research study funded by the National Institute of Diabetes, Digestive Diseases and Kidneys within the National Institutes of Health. The study looks at a combination of cognitive behavioral therapy and exercise for individuals with type 2 diabetes to be used as a model of an interdisciplinary approach to the treatment of depression in diabetes.

Dr. de Groot has contributed more than 80 articles and presentations on the psychosocial aspects of type 1 and type 2 diabetes.

Dr. de Groot’s work on treatment of depression for those with diabetes is another example of how IUPUI faculty are TRANSLATING RESEARCH INTO PRACTICE.

Browse

Browsing Mary de Groot by Subject "African American health"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Type 2 Diabetes Genetic Risk Scores Are Associated With Increased Type 2 Diabetes Risk Among African Americans by Cardiometabolic Status
    (Sage, 2018-01-03) Layton, Jill; Li, Xiaochen; Shen, Changyu; de Groot, Mary; Lange, Leslie; Correa, Adolfo; Wessel, Jennifer; Epidemiology, School of Public Health
    The relationship between genetic risk variants associated with glucose homeostasis and type 2 diabetes risk has yet to be fully explored in African American populations. We pooled data from 4 prospective studies including 4622 African Americans to assess whether β-cell dysfunction (BCD) and/or insulin resistance (IR) genetic variants were associated with increased type 2 diabetes risk. The BCD genetic risk score (GRS) and combined BCD/IR GRS were significantly associated with increased type 2 diabetes risk. In cardiometabolic-stratified models, the BCD and IR GRS were associated with increased type 2 diabetes risk among 5 cardiometabolic strata: 3 clinically healthy strata and 2 clinically unhealthy strata. Genetic risk scores related to BCD and IR were associated with increased risk of type 2 diabetes in African Americans. Notably, the GRSs were significant predictors of type 2 diabetes among individuals in clinically normal ranges of cardiometabolic traits.